Improves wakefulness in patients w/ excessive daytime sleepiness associated w/ narcolepsy. Excessive sleepiness associated w/ moderate to severe chronic shift work sleep disorder where non-pharmacological interventions are unsuccessful or inappropriate. Adjunct to continuous positive airways pressure (CPAP) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.
Narcolepsy, obstructive sleep apnoea/hypopnoea syndrome (OSAHS) 150 mg or 250 mg once daily in the morning. Shift work sleep disorder (SWSD) 150 mg daily approx 1 hr prior to the start of work shift.
Discontinue treatment if multi-organ hypersensitivity reaction is suspected, if any signs/symptoms suggesting angioedema or anaphylaxis (eg, swelling of face, eyes, lips, tongue or larynx; difficulty in swallowing or breathing; hoarseness) is observed, occurrence of serious rash, including SJS. Frequently reassess the degree of sleepiness & advise to avoid driving or any potentially dangerous activity in patients w/ excessive sleepiness. History of psychosis, depression, or mania. Recent history of MI or unstable angina. Should not be used in patients w/ history of left ventricular hypertrophy or w/ mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. Increased monitoring of heart rate & BP during therapy. Patients w/ known CV disease. History of drug &/or stimulant abuse; observe for signs of misuse or abuse. Severe hepatic impairment (w/ or w/o cirrhosis); renal impairment. Caution in operating an automobile or other hazardous machinery. Potential increased risk of pregnancy when using steroidal contraceptives during therapy & for 2 mth after discontinuation of therapy. Higher mean plasma levels of γ-glutamyltransferase & alkaline phosphatase following administration of Nuvigil. Pregnancy & lactation.
Sign Out
